HS-10342

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorHR+/HER2- Advanced and/or Metastatic Breast Cancer

Phase 1

A Study of HS-10342 in Patients With Advanced Solid Tumor

CompletedNCT04060511

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2019-06-19End: 2021-09-15Updated: 2023-03-09

Phase 2

A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.HR+/HER2- Advanced and/or Metastatic Breast Cancer

Start: 2021-09-30End: 2023-12-31Target: 20Updated: 2021-09-16